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The arachidonate 15-1ipoxygenase  which is expressed in atherosclerotic lesions is implicated in 
the oxidative modification of low density lipoproteins during atherogenesis.  To obtain egperirnental 
in vivo evidence for this hypothesis, we analyzed the structure of oxygenated lipids isolated from 
the aorta of rabbits fed with a cholesterol-rich diet for different time periods and compared the 
pattern of oxygenation products with that isolated from low density lipoproteins treated in vitro 
with the pure rabbit 15-1ipoxygenase  and with oxygenated lipids isolated from advanced human 
atherosclerotic  lesions.  In early  atherosclerotic  lesions  (12-wk  cholesterol  feeding),  specific 
lipoxygena~ products were detected whose structure was similar to those isolated  from lipoxygenase- 
treated low density lipoproteins. The appearance of these products did coincide with the lipid 
deposition in the vessel wall. In later stages of atherogenesis (26-wk cholesterol feeding) the 
degree of oxidative modification of the tissue lipids did increase  but the share of specific  lipoxygemse 
products was significantly lower, suggesting an increasing overlay of the specific lipoxygenase 
products by nonenzymatic lipid peroxidation.  In advanced human atherosclerotic lesions, large 
amounts of oxygenation products were detected whose structure suggests a nonenzymatic  origin. 
These data suggest that the arachidonate 15-lipoxygenase is of pathophysiological importance 
during the early stages of atherogenesis. In later stages of plaque development nonenzymatic 
lipid peroxidation  becomes more relevant. 
herosclerosis  is a multifactorial  disease  with great socioeco- 
nomic impact. Although a substantial body of research 
has been carried out during the last decades, the molecular 
mechanisms of atherogenesis are not fully understood (1, 2). 
The development of atherosderotic lesions, which is charac- 
terized by inflammatory and hyperproliferative processes as 
well as by lipid deposition, may be regarded as a protective 
response  to an injury of the vessel  wall (1). A variety of  growth 
factors, cytokines, adhesion molecules, and vasoactive sub- 
stances are implicated in plaque development. A key process 
in atherogenesis appears to be the development of lipid-Ioaded 
foam cells that accumulate in the subendothelial space to form 
fatty streaks, that are generally accepted  as early atherosclerotic 
lesions (3, 4). Foam cells may develop from peripheral mono- 
cytes/macrophages or from smooth muscle cells by taking 
up modified low density lipoproteins (LDL) 1 via scavenger 
1 Abbreviations used in thispaper: CP-HPLC, chiral phase HPLC; GC/MS, 
gas chromatography/mass spectrometry; HETE, hydroxy-eicosatetraenoic 
acid; HODE, hydraxy-octadecadienoic  add; LDL, low density lipoprotein; 
NZW, New Zealand White; RP-HPLC, reverse  phase HPLC; SP-HPLC, 
straight phase HPLC. 
receptor-mediated  pathways (5, 6). The chemical nature of 
the modifying  processes  in vivo is not completely understood. 
However, the occurrence of oxidatively modified lipoproteins 
in atherosderotic lesions (7, 8) and the fact that oxidativdy 
modified LDL is taken up rapidly by macrophages (9) sug- 
gested an involvement of oxidative processes in foam cell 
formation. Copper ions effectively  oxidize LDL into its athero- 
genic form (10, 11). The oxidative modification of LDL in 
various cellular systems (12-14) was prevented by nonspecific 
lipoxygenase inhibitors, suggesting a role for the 15-lipoxy- 
genase pathway. This hypothesis was supported by the im- 
munohistochemical detection of the 15-lipoxygenase in ath- 
erosclerotic lesions of rabbits and humans (15, 16). Ex vivo 
studies indicated that the lipoxygenase  was enzymatically  active 
in the lesion (17, 18). Further evidence for the implication 
of the 15-lipoxygenase  in atherogenesis was provided by the 
recent finding that the purified enzyme in vitro is capable 
of oxidatively modifying human LDL into its atherogenic 
form (19, 20). On the other hand, more quantitative inhib- 
itor studies indicated that rabbit aortic endothelial cells and 
mouse peritoneal macrophages are capable of oxidizing LDL 
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suggests that cellular lipoxygenases are not essential for ox- 
idative modification of LDL. However, these in vitro data 
do not exclude an implication of the 15-1ipoxygenase  in the 
development of atherosderotic lesions in vivo. The high ex- 
pression level of this enzyme in lesions of animal atherosde- 
roils models (15) and humans (16) and its absence in normal 
vessel waft suggest its involvement in atherogenesis. Hydroxy 
fatty acids have been detected in the atherosderotic tissue of 
humans  (22,  23) and rabbits (24) but their exact chemical 
structure and the mechanism  of biosynthesis has not been 
studied. 
Investigations on the in vivo action of the 15-1ipoxygenase 
have been hampered by the lack of specific  15-1ipoxygenase 
inhibitors and of transgenic animals. There is, however, an- 
other approach for this problem. In biological samples lipoxy- 
genases leave behind a specific product pattern that can be 
differentiated from unspecific nonenzymatic oxygenation prod- 
ucts.  Thus,  we analyzed the lipid extracts  of the aorta of 
cholesterol-fed rabbits for the occurrence of specific lipoxy- 
genase products during the time course of plaque develop- 
ment and compared the product pattern with that of the in 
vitro interaction of the isolated 15-1ipoxygenase with human 
LDL. These experiments, as well as the data on the lipid com- 
position of advanced human atherosclerotic lesions, suggest 
that the 15-1ipoxygenase is of pathophysiological importance 
in early atherogenesis,  whereas nonenzymatic lipid peroxi- 
dation is more prominent  in later stages. 
Materials  and Methods 
Chemicals 
The chemicals used were from the following sources: 9Z,12Z- 
octadecadienoic acid (linoleic add), 5Z,SZ,11Z,14Z-eicosatetraenoic 
acid (arachidouic acid), (D/L)-c~-toeopherol, soybean lipoxygenase 
(grade 1), cholesteryl linoleate, and cholesteryl arachidonate from 
Serva (Heidelberg, FRG). All solvents used (Serva) were of HPI.C 
grade. 
Preparations 
Human LDL was obtained by sequential floating ultracentrifu- 
gation in a sodium bromide density gradient (25). The LDL prep- 
aration  was dialyzed against  isotonic  sodium  chloride  solution 
containing 3 mM EDTA. Rabbit reticulocyte lipoxygenase and the 
recombinant  human 15-lipoxygenase were prepared as described 
before (19, 20). Authentic HPLC standards of racemic 13-hydroxy- 
9Z,11E-octadecadienoic acid (13-HODE) and 9-hydroxy-10E,127_, 
octadecadienoic acid (9-HODE) were prepared by vitamin E-con- 
trolled autoxidation of fatty add methyl esters (26). After triphenyl- 
phosphine  reduction  and  alkaline hydrolysis, the resulting  free 
hydroxy fatty add isomers were separated by straight  phase (SP) 
HPLC.  Chiral  standards  of  13S-HODE  and  15S-HETE  (15S 
hydroxy-5Z,SZ,11Z,13E-eicosatetraenoic  acid) were obtained by en- 
zymatic  oxygenation  (27) of linoleic acid and arachidonic acid, 
respectively, followed by HPLC preparation of the major oxygena- 
tion products. The chemical structure of all reference compounds 
prepared was confirmed by UV spectroscopy,  HPLC indnding chiral 
phase (CP) HPLC, and gas chromatography/mass  spectrometry 
(GC/MS) of the trimethylsilyl ethers and their hydrogenated de- 
rivatives. 
LDL Oxygenation.  Human LDL was incubated with the rabbit 
15-lipoxygenase or with the recombinant human 15-1ipoxygenase 
in 0.1 M phosphate buffer, pH 7.4 (assay  volume 2 ml), for 15 rain. 
The final EDTA concentration  in the incubation mixture was ad- 
justed to 1 raM. The reaction was stopped by the addition of so- 
dium borohydride to reduce the hydroperoxy compounds to their 
corresponding alcohol 15S-hydroxy-11Z,13E-eicosadienoic  acid was 
added as an internal standard and the lipids were extncted according 
to the method of Bligh and Dyer (28). After evaporation of the 
solvents, the lipids were reconstituted in 1 ml of methanol/chloro- 
form (8:2 by col) and an aliquot (150 #1) was analyzed by reverse 
phase (RP) HPLC for oxygenated chohsterol esters and for free 
cholesterol content.  150 #1 of 40% KOH was added to the re- 
maining lipid extracts and the lipids were hydrolyzed for 30 rain 
at 60~  under argon atmosphere. As shown earlier, this method 
completely  hydrolyzes the ester  lipids  and  does  not lead to  a 
significant formation  of autoxidation  products  (19). 
Animal Experiments 
Cholesterol  Feeding.  Male New Zealand White (NZW) rabbits 
(3.0 + 0.2 kg body weight) were purchased from Interfanna U.K. 
Ltd. (Huntington, UK) and housed individually in phstic wire- 
bottomed cages according to European guidelines for the caging 
of small rodents and rabbits. The animals were fed a standard chow 
diet (Sniff Spezialdiiten GmbH, Soest, FRG) and water ad libidum. 
For the cholesterol feeding experiments, this diet was supplemented 
with 1% pure cholesterol (cholesterol-rich diet). The animals were 
categorized into four groups: group 1, 5 rabbits fed for 12 wk with 
the standard diet (control  group);  group 2, 10 rabbits fed for 6 
wk with the cholesterol-enriched standard diet; group 3, 13 rabbits 
fed for 12 wk with the cholesterol-enriched standard diet (included 
two series of experiments, a pilot one with 3 rabbits, a second one 
with 10 rabbits); and group 4, 9 rabbits fed for 26 wk with the 
cholesterol-enriched standard diet. 
Watanabe Rabbits.  14-wk-old  Watanabe rabbits were purchased 
from Froxfield Farms Ltd. (Hampshire, UK) and fed with a stan- 
dard diet for 280 d (40 wk) under the same conditions as the NZW 
rabbits. 
Blood and Tissue Samples.  For the determination  of the serum 
cholesterol concentration, blood was withdrawn from the ear vein 
and the cholesterol content was determined by the CHOD-PAP 
method (Boehringer Mannheim GmbH Diagnostica, Mannheim, 
FRG). The animals were killed by an overdose  injection of  phenobar- 
bital; the aortas were removed, shock frozen in liquid nitrogen, 
and stored at  -80~  or in liquid nitrogen  until sample work-up. 
Human Atherosclerotic Tissue 
Samples of human atherosclerotic lesions were removed during 
thrombaterectomy or endaterectomy because of clinical indications. 
The tissue samples were shock frozen and stored on dry ice or in 
liquid nitrogen.  Sample work-up was carried out as described for 
the animal material. 
Workup of the Tissue Samples 
After thawing of the tissue samples, areas with macroscopically 
visible atherosclerotic alterations (fatty streaks and advanced phques) 
were prepared. Typically, samples of 2ill-l,000 rag wet weight were 
prepared and the lipids were extracted (28). Briefly, the tissue samples 
were homogenized in 4.75 ml of a mixture of PBS/methanol/chlo- 
roform (1:2.5:1.25 by vol) with an Ultraturrax microhomogenizer 
(Janke-Kunkel GmbH & Co. KG, Staufen, FRG) three times for 
30 s with a 2-rain break between the homogenization  steps. To 
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homogenization was carried out under argon atmosphere on ice. 
After addition of 15S-hydroxy-11Z,13E-eicosadienoic acid as an in- 
ternal standard, the homogenate was kept on ice for 30 min. 1.25 
ml of water and 1.25 ml of chloroform were then added, and the 
mixture was vortex~d for 60 s and centrifuged for phase separation 
for 10 rain at 10,000 g. The lower chloroform phase which con- 
tained the total tissue lipids was recovered, the solvent was evapo- 
rated, the lipids were reconstituted in 1 ml of a mixture of chloro- 
form/methanol (2:8, by vol), and aliquots (150 #1) were analyzed 
for oxidized cholesterol esters and for the free cholesterol content 
by RP-HPLC. The remaining extracts were subjected to alkaline 
hydrolysis (addition of 0.15 ml of 40% KOH and incubation for 
30 min at 60oc under argon atmosphere). Afterwards, the samples 
were acidified by the addition of 0.1 ml of glacial acetic acid and 
aliquots were directly injected to RP-HPLC for the determination 
of the degree  of oxidation of the tissue lipids. 
Analytics 
HPLC was carried out on a Shimadzu instrument (Tokyo,  Japan) 
coupled with a diode array detector (model 1040 A; Hewlett-Packard 
Co., Palo Alto, CA). The lipoxygenase reaction differs from the 
nonenzymatic lipid peroxidation with respect to its high reaction 
spedficity.  This specificity can be quantified by various methods 
the most suitable of which appears to be the determination of the 
enantiomer composition (S-isomer/R-isomer ratio [28a]) of the 
major oxygenation product  (13-hydroxy-9Z,11E-octadecadienoic 
acid). The lipoxygenase reaction is characterized by a strong prepon- 
derance of the S-isomer whereas nonenzymatic reactions  lead to 
a racemic mixture (S/R-ratio, 1:1). According to our experience 
with post-mortem samples of advanced human atherosclerotic  le- 
sions (23) five consecutive  steps of HPLC are necessary (Table 1) 
in order to analyze the enantiomer composition of the 13-hydroxy- 
9Z,11E-octadecadienoic acid present in the lesions. By analytic RP- 
HPI.C (step 1) the degree of oxidative modification of the tissue 
lipids (hydroxy polyenoic fatty acid/polyenoic fatty acid ratio) was 
determined by simultaneous measurement of the concentration of 
hydroxy polyenoic fatty acids and nonoxygenated polyenoic fatty 
acids in the hydrolyzed lipid extracts. As step 2 of the HPI.C pro- 
tocol, a preparative RP-HPLC was introduced to prepare the oxy- 
genated polyenoic fatty acids which constitute a mixture of var- 
ious positional and geometric isomers of  hydroxy  and keto polyenoic 
fatty adds. By analytic SP-HPLC (step 3) this mixture was sepa- 
rated into its constituents and the percentage of the 13-HODE, 
which was shown to be the major oxygenation product, was de- 
termined. This product was prepared by SP-HPLC (step 4) and sub- 
sequently analyzed for its enantiomer composition by CP-HPI.C 
(step 5). RP-HPLC was performed on a Nucleosil  C-18 column 
(Macherey/Nagel, D~en, FRG, KS-system, 250  x  4 ram, 5-#m 
particle  size).  A  solvent  system  of methanol/water/acetic acid 
(82:18:0.1 by vol) and the flow rate of 1 ml/min were used. The 
fractions containing the oxygenated polyenoic fatty acids were col- 
lected, the solvent was evaporated,  the residue was reconstituted 
in a mixture of n-hexane/2-propanol/acetic acid (100:2:0.1 by vol) 
and injected for SP-HPLC purification of the 13-HODE(Z,E). SP- 
HPLC was carried out on a Zorbax SIL column (DuPont, Wil- 
mington, DE; 250  x  4.6 mm, 5-#m particle size) with a solvent 
system of n-he~ane/2-propanol/acetic acid (100:2:0.1 by vol) and 
a flow rate of I ml/min. Fractions containing 13-hydroxy-9Z,11E- 
octadecadienoic acid were collected, concentrated under vacuum, 
and the enantiomer composition was determined by CP-HPLC 
which was carried out on a Chiralcel OD column (Diacel Chem. 
Industries, Kyoto,  Japan; 250  x  4.6 mm, 5-#m particle size) with 
a solvent system of hexane/2-propanol/acetic  acid (100:5:0.1 by vol) 
and a flow rate of I ml/min. Oxygenated cholesterol  esters were 
analyzed by RP-HPLC with a solvent system of 2-propanol/acetoni- 
trile (25:75 by vol) and a flow rate of 1 ml/min at 45~  Com- 
pounds were generally identified by coinjections  with authentic 
standards. Chromatograms were quantified by peak areas. Calibra- 
tion curves (5-point measurements)  were established for free cho- 
lesterol, linoleic, arachidonic and 13-hydroxy-gz,11E-octadecadienoic 
acid. 
GC/MS.  GC/MS was performed on a GC/MS system (Hew- 
lett-Packard)  equipped  with a capillary  RSb150  column (poly- 
dimethylsiloxane,  0.25-#m coating thickness;  30 m  x  0.32 mm; 
Research Separation Labs., Eke, Belgium). The hydroxy fatty acids 
prepared by SP-HPLC were methyhted with diazomethan,  silyLated 
with bis-(trimethylsilyl)-trifluoroacetamide  and than injected  to 
CG/MS. For more informative mass spectra hydrogenation of the 
hydroxy fatty acid methyl esters was carried out in some cases. 
Statistics.  Significance calculations  (Students t test) were per- 
formed with the StatWorks 1.2. software package on a Macintosh 
SE personal computer. 
Resuks 
Oxygenation 
lipoxygenases. 
of Human  LDL  by  Pure  Mammalian  15- 
The 15-1ipoxygenases of rabbits and humans 
Table  1.  Scheme of Consecutive Steps of HPLC for the Quantification of the Share of Specific Lipoxygenase Products in Tissue Lipid 
Step  HPLC  Purpose  Information obtained 
1  RP-HPLC  Analytical 
2  RP-HPLC  Preparative 
3  SP-HPLC  Analytical 
4  SP-HPLC  Preparative 
5  CP-HPLC  Analytical 
Determination of the hydroxy linoleic acid/linoleic acid ratio (%) as a 
measure  for the degree of oxidative modification of tissue lipids 
Preparation  of the sum of the oxygenated polyenoic fatty acids (hydroxy 
and keto derivatives) 
Separation  of the positional (9- and 13-HODE)  and geometric isomers  (Z,E- 
and E,E- isomers)  of the hydroxy and keto fatty acids 
Isolation of pure  13(K/S)-HODE(Z,E)  for enantiomer analysis 
Analysis of the enantiomer composition of 13(S/K)-HODE(Z,E) 
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Figure  1.  R.P-HPI.C  of oxygenated  poly- 
enoic  fatty  adds of  lipoxygetme-treated  human 
LDL. Human  LDL (2 nmol  apoprote/n  B) was 
incubated with the pure rabbit reticulocyte 
lipoxygetme  (4 nkat/ml  linoleate  oxygetme  ac- 
tivity) which  corresponds  to 2 nmol  of  the en- 
zyme (molar  lilxmygenase/apoprotein  B ratio 
of 1:1) for 15 min at 25~  After addition  of 
sodium borohydride the sample was acidified 
to pH 3, the lipids were ~tracted, and the e~- 
tracts were hydrolyzed under alkaline condi- 
tions. R.P-HPLC was carried out as described 
in Materials and Methods. (~p) Absorbance 
at 235 nm for analysis of the conjugated dienes 
(hydroxy polyenoic fatty adds); (bottom) absor- 
bance at 210 nm for analysis of the nonoxy- 
genated polyenoic fatty acids. (LEA) Linolenic 
add; (EPA) eicosapentaenoic add; (DA) docosa- 
he~aenoic acid; (AA) arachidonic  acid; (LA) 
linoleic acid. (Inset)  Determination of the enan- 
tiomer  composition  of  13-hydroxy-9Z,11E- 
octadecadienoic  acid (13.HODE) isolated by 
ILP- and SP-HPLC. 
are capable of oxygenating human LDL in vitro (19, 20). 
RP-HPI.C of the hydrolyzed lipid extracts indicate the for- 
mation of oxygenated polyenoic fatty adds comigrating with 
an authentic standard of 13-hydroxy-9Z,11E-octadecadienoic 
acid (Fig. 1, top). The UV-spectrum of these compound(s) 
showed a characteristic conjugated diene chromophore with 
an absorbance maximum at 234 nm. Control incubation of 
LDL with the heat-denattaed enzyme or without lipoxygenase 
showed only a small peak at this retention time (<10% of 
the peak detected in lipoxygenase-treated LDL). Recording 
the chromatogram at 210 nm (Fig.  1, bottom), the nonoxy- 
genated polyenoic fatty acids were analyzed. Quantification 
of the chromatograms at both wavelengths (235 and 210 nm) 
allowed the calculation of the hydroxy polyenoic fatty acid/ 
polyenoic fatty acid ratio, which is a suitable measure for the 
oxidative modification of the LDL lipids. For LDL oxygena- 
tion, this ratio varied between 0.5 and 4%,  depending on 
the incubation time, on the amount of lipoxygenase added 
(lipoxygenase loading of the LDL particle), and also on the 
LDL concentration. As major oxygenation product, esterified 
13S-hydroxy-9Z,11E-octadecadienoic  acid was identified by 
straight (data  not shown) and chiral  phase-HPLC (Fig.  1, 
inset) as well as by GS/MS. These compounds were mainly 
located in the cholesterol ester fraction, but also in various 
phospholipid classes of the LDL particle (19). 
In contrast to the specific product pattern of the lipoxy- 
genase-catalyzed LDL oxidation, the nonenzymatic copper- 
catalyzed oxidation of human LDL led to unspecific oxygen- 
ation products with 13-hydroxy-9Z,11E-octadecadienoic acid 
and 9-hydroxy-10E,12Z-octadeeadienoic acid (ratio 1:1) being 
the major oxygenation products (data not shown). Both com- 
pounds were racemic mixtures with an equal distribution of 
the S- and R-enantiomer (S/R-ratio 1:1). Thus, analyzing 
the enantiomer composition of the major oxygenated lipids 
of in vivo samples one may differentiate between lipoxygenase 
catalyzed  and nonenzymatic LDL oxygenation. 
Oxygenated Lipids in Advanced Human Atherosclerotic Le- 
sions.  Arachidonate 15-1ipoxygenase is expressed in foamy 
macrophages of human atherosclerotic lesions (16), but the 
question of whether this enzyme acts in vivo on endogenous 
lipids including LDL has not been investigated so far. Since 
enzymatic oxidation of LDL can be differentiated from nonen- 
zymic oxidation processes by its specific product pattern, we 
analyzed  atherosclerotic lesions obtained from 10 different 
patients during endaterectomy for the occurrence of oxidized 
lipids and determined the specificity of these compounds. We 
found that advanced human lesions (cholesterol  content of 
the lesions: mean 25.4 mg/g wet weight, SD 9.9 mg/g wet 
weight) contain large amounts of oxygenated polyenoic fatty 
adds, mainly 9- and 13-hydroxy linoleic acid isomers (Fig. 
2), and in smaller amounts the corresponding keto deriva- 
tives. The degree of oxidation of the lesion lipids varied be- 
tween 3 and 10% (mean 5.5%, SD 2.7%), e.g., in some cases 
up to 10% of all linoldc acid residues in the lesion were present 
as oxygenated derivatives. CP-HPLC (Fig. 2, inset) of the 13- 
hydroxy-9Z,11E-octadecadienoic acid isolated from advanced 
lesions indicated an equal distribution of the S- and the R- 
isomer (share of the S-isomer: mean 50.0%, SD 1.6%) sug- 
gesting a nonenzymatic origin. These results which are in 
line with our earlier findings on the structure elucidation 
of  oxygenated  lipids  in  post-mortem  samples  of  human 
atherosderotic lesions (23) suggest that the majority of oxy- 
genation products are formed by nonenzymatic lipid peroxi- 
dation. 
Oxygenated Lipids in the Time Course of  Plaque Development 
in Animal Models of Atherosclerosis.  The deposition of lipids 
in developing human atherosderotic lesions is a long-lasting 
process that takes years or even decades. During this time 
the lipids may undergo autooxidation after being deposited 
in the plaque.  This nonspedfic autooxidation may overlap 
the specific lipoxygenase reaction that is implicated in the 
initial phase of plaque development. To get information on 
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Figure 2.  SP-HPLC of the oxygenated polyenoic fatty acids isohted 
from advanced human atherosclerotic lesions. A human atheroma was re- 
moved during thromboaterectomy from a 35-yr-old patient suffering from 
severe stenosis of the right A. carotis.  Aftes removal, the tissue was shock 
frozen  and  stored  in  liquid  nitrogen.  Sample  work-up,  RP-HPLC 
purification, and SF-HPI.C analysis  of the oxygenated polyenoic fatty acids 
were described in Materials and Methods. The chemical structure of the 
compounds ehted is given above the traces. (Inset) CP-HPLC analysis of 
the 13-hydroxy-9Z,11E-octadecadienoic  acid (a) isolated by SP-HPI.C. 
the oxidative reaction in early atherogenesis, we analyzed the 
specificity of the oxidation products during the time course 
ofphque development in cholesterol-fed rabbits. For this pur- 
pose,  NZW rabbits were categorized into four groups ac- 
cording to the duration of cholesterol feeding (see Materials 
and Methods). At the beginning of the feeding period, the 
serum cholesterol content of all rabbits was determined. No 
significant differences in the serum cholesterol levd were found 
between the various groups. After killing the animals,  the 
aortas were removed, areas with atherosclerotic lesions were 
prepared, the lipids were extracted, and the extracts were ana- 
lyzed by HPLC for the following three parameters: (a) cho- 
lesterol content of the aorta lipid extracts (RP-HPLC) as in- 
dicator for the lipid deposition in the vessd wall; (b) degree 
of oxidative modification of the tissue lipids (calculation of 
the hydroxy linoleic add/linoleic acid ratio from RP-HPLC 
analysis); and (c) enantiomer composition (S/R ratio) of the 
major  oxygenation product (13-hydroxy-gZ,11E-octadeca- 
dienoic acid) reflecting the specifidty of the oxygenation reac- 
tion (CP-HPLC). In addition, the serum cholesterol level at 
the end of the feeding period was determined. Representa- 
tive HPLC chromatograms of the enantiomer analysis (Fig. 
3) are shown. Table 2 demonstrates that cholesterol feeding 
led to a drastic increase in the serum cholesterol level after 
a 6-wk feeding period, but did not further increase if the 
rabbits were fed with the cholesterol-rich diet for a longer 
time period. In contrast, the cholesterol content of the aorta 
did not increase during the first 6 wk of cholesterol feeding. 
These data  are  in line with  earlier  observations that  no 
sudanophil areas were detectable after a 6-wk feeding period 
under our experimental conditions. After a 12-wk fe~ling 
period, the cholesterol content of the aorta strongly increased 
and large sudanophil areas were detected (data not shown). 
These results indicate that under our experimental conditions 
the lipid deposition in the vessd wall started between 6 and 
12 wk of cholesterol feeding and suggest that the atheroscle- 
rotic changes observed after a 12-wk feeding period may be 
regarded as early developing lesions. After 26 wk of feeding, 
the cholesterol content of the aorta did further increase, indi- 
cating a continuation of lipid deposition. 
The degree of oxygenation of the aorta lipids in the con- 
trol animals of about 0.16% was somewhat higher than that 
of other rabbit tissues (lung, kidney, liver, and skeletal muscle) 
where 0.1% of all linoleate residues were found to be oxy- 
genated. Cholesterol feeding tended to lead to an increase 
in the degree of oxygenation of the tissue lipids which was 
not significant  after  12 wk of feeding because of the large 
interindividual differences. After 26 wk, a further increase 
in the degree of oxygenation was detected which was fig- 
nificant (p =  0.02) when compared with the 12-wk feeding 
period. Summarizing these data, one may conclude that there 
are subtle but no drastic changes in the degree of oxidation 
of tissue lipids in early stages of plaque development. Thus, 
the hydroxy polyenoic fatty acid/polyenoic fatty acid ratio 
does not appear to be a suitable parameter to differentiate 
between various stages of plaque development in early athero- 
genesis. 
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Figure 3.  Enantiomer composi- 
tion  of  13-bydroxy-9Z,11E-octa- 
decadienoic add during the time 
course of cholesterol feeding.  13- 
HODE was isolated from the aorta 
of cholesterol-fed rabbits  by con- 
secutive steps of KP- and SP-HPLC. 
CP-HPLC  was cm'ied out as de- 
scribed in Materials and Methods. 
The cholesterol  feeding  period  is in- 
dicated  above  the traces. R~presen- 
tative  chromatograms for  the 
different groups are shown. The 
enantiomers  (R- and S-isomer)  wece 
identified  by coinjcctions  with au- 
thentic  chiral  and racemic  standards. 
1907  K~lhn et al. Table  2.  Time-dependent  Changes of the Lipid Composition of the Pe@heral Blood and the Aorta during Feeding of Rabbits with 
a Cholesterol-rich Diet 
No. of animals 
Degree of oxidative 
Serum cholesterol  Aorta cholesterol  modification of tissue  Product  specificity 
content  content  lipids (hydroxy linoleic  (share of the S-isomer 
(mg/ml serum)  (mg/g wet weight)  acid/linoleic acid ratio)  of 13-HODE) 
Group  Mean  SD  Significance Mean  SD  Significance Mean  SD  Significance Mean  SD  Significance 
1/control  5  22.4  5.1 
2/6-wk  <0.001" 
feeding  7  1,500  385 
3/12-wk  0.228 
feeding  13  1,790  622 
4/26-wk  0.070 
feeding  9  1,300  460 
%  % 
2.8  0.3  0.166  0.05  51.0  2.0 
0.01"  0.003* 
1.8  0.6  ND  54.1  1.9 
<0.001  0.303  <0.001 
8.0  4.0  0.276  0.22  73.7  10.6 
0.030  0.020  0.003 
12.2  3.0  0.589  0.42  60.2  6.8 
NZW rabbits were  categorized  into four groups and fed with a cholesterol-enriched  standard diet as described  in Materials and Methods. After killing 
the animals, the aortas were recovered,  pieces with atherosclerotic  lesions were prepared, and the total tissue lipids were e~tracted (24). Analysis  of 
the parameters  was carried out as described in Materials and Methods. 
*Significance  calculations were carried out in comparison with the data of the next shorter feeding period. 
The specificity of the oxygenation products, which is an 
indicator for the in vivo action of the 15-1ipoxygenase, showed 
an unusual time course. In the control group the 13-HODE 
isolated from the aorta was a racemic mixture with an equal 
distribution of S- and K-isomers indicating the absence of 
lipoxygenase activity. After 6 wk of cholesterol feeding, there 
was a slight but significant increase in the product specificity, 
suggesting a small but detectable share of the lipoxygenase 
in the biosynthesis of the oxygenation products. After 12 wk 
of feeding, the product pattern became much more specific. 
The S/R ratio of the 13-hydroxy-9Z,11E-octadecadienoic  acid 
of about 7:3 differs significantly from that of the control group 
and from that of the 6-wk feeding group, indicating the in 
vivo action of the 15-lipoxygenase in the developing lesion. 
It may be of pathophysiological importance that the in vivo 
action of the 15-lipoxygenase coincided with the beginning 
of the lipid deposition into the vessel wall. After 26 wk of 
cholesterol feeding the product pattern again became more 
unspecific,  suggesting an overlay of the specific lipoxygenase 
products by nonenzymatic lipid peroxidation products. 
In an additional set of experiments, the aortas of 9-mo-old 
Watanabe rabbits (n =  9) were analyzed for oxygenated poly- 
enoic fatty acids. Both the serum cholesterol level (mean 347.8 
mg/ml blood, SD 44.5 mg/ml) and the cholesterol content 
of the aorta (mean 11.3 mg/g wet weight, SD 2.3 mg/g wet 
weight) were significantly increased as compared with con- 
trol rabbits fed with the same standard diet. The specificity 
of the oxygenation products measured as the share of the 
S-enantiomer of 13-HODE (mean 58.6%,  SD 5.2%)  was 
comparable with that of the rabbits fed with a cholesterol- 
rich diet for 26 wk (mean 60.2%, SD 6.8%). However, the 
specificity was significant higher (p =  0.01) than in the con- 
trol group but lower (p  =  0.003) than in the 12-wk feeding 
group. These data suggest action of a 15-1ipoxygenase in the 
lesions of 9-mo-old Watanabe rabbits.  Here again, the specific 
share of lipoxygenase products is strongly overlaid by unspecific 
oxygenation products which probably originate from nonen- 
zymatic lipid peroxidation. 
Discussion 
The arachidonate 15-lipoxygenase is implicated in athero- 
genesis because it is expressed in foamy macrophages (15, 16) 
and is capable of oxidativdy modifying LDL into its athero- 
genic form (19, 20). However, since no specific 15-1ilx~jgenase 
inhibitors and no transgenic animals are available so far, in- 
vestigations on the role of the 15-lipoxygenase in atherogen- 
esis have focused on in vitro experiments with cellular (12-14) 
and molecular model systems (19). As with any model, these 
systems may not necessarily reflect the events going on in 
developing atherosderotic plaque.  The detection of specific 
lipoxygenase  products  in  early  atherosderotic  lesions  of 
cholesterol-fed rabbits is not a direct proof for their lipoxy- 
genase origin. However, the formation of these products can 
be explained by the action of the lipoxygenase which is present 
in the lesion in an enzymatically active form (15-18). In later 
stages of plaque development, unspecific nonenzymatic oxy- 
genation reactions become more prominent. These data in- 
dicate that the pathogenesis of atherosderosis involves both 
enzymatic and nonenzymatic lipid peroxidation. It may be 
hypothesized that, by providing hydroperoxy  lipids, the lipoxy- 
genase may act  as  an initiator  of an oxidative cascade  in 
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as source for flee radical-mediated propagation reactions which 
lead to a more unspecific product pattern. Under physiolog- 
ical conditions, hydroperoxy lipids are rapidly reduced in cel- 
hlar systems to hydroxy derivatives by ghtathione-dependent 
hydroperoxidases,  such as the phospholipid hydroperoxide 
glutathione peroxidase (29, 30). This reduction does not in- 
volve the formation of free radicals (31) and therefore may 
counteract free radical-mediated propagation reactions. How- 
ever, if the reductive capacity of the cells is exceeded by the 
cellular hydroperoxide content, radical-mediated hydroperox- 
idase reactions become dominating. These radical-mediated 
hydroperoxidase reactions,  which are usually initiated by a 
homolytic cleavage of the hydroperoxy group leading to the 
formation of flee alkoxy and hydroxy radicals, may be cata- 
lyzed by transition metals but also by hemoproteins (32). The 
radical intermediates may induce secondary lipid peroxida- 
tion leading to an unspecific pattern of oxygenation products. 
According to our data, the formation of the specific lipoxy- 
genase products coincides with the beginning of the lipid 
deposition in the vessel wall during the time course of cho- 
lesterol feeding. Thus a causal relationship between the ac- 
tion of the 15-1ipoxygenase and the lipid deposition may be 
discussed. Our data, of course, do not prove that the in vivo 
action of the lipoxygenase is the reason for the lipid deposi- 
tion. It may even be the other way around. However, since 
oxidative modification of LDL into its atherogenic form is 
implicated in early atherogenesis (33, 34) the in vivo action 
of the lipoxygenase may contribute to this process. 
In vitro, the 15-1ipoxygenase is capable of oxidizing both 
lipoproteins and cellular membranes without the preceding 
action of any lipid-cleaving enzyme such as phospholipase 
or cholesterol ester hydrolase. Analyzing the hydrolyzed lipid 
extracts  of atherosclerotic aortas  it  is not possible to tell 
whether the lipoxygenase in the lesion oxygenates cellular 
membranes or LDL ester lipids. However, the detection of 
specific lipoxygenase products in the cholesterol ester frac- 
tion, which are not normal constituents of biomembranes 
indicates  that the enzyme in vivo catalyzes at least in part 
a direct oxygenation of LDL. Alternatively, the lipoxygenase 
may act intracellularly,  oxygenating the plasma membrane 
phospholipids of macrophages. Such a lipoxygenase-catalyzed 
membrane oxidation has been reported for rabbit reticulo- 
cytes (35) and IL-4-treated human peripheral monocytes (36). 
The hydroperoxy lipids may then exchange with LDL lipids 
and induce secondary oxygenation of the LDL. Recent studies 
on the oxidative modification of LDL by J-774.A1 cells sug- 
gested that LDL oxidation requires binding of the LDL par- 
tide to its membrane receptor (37).  Such a binding is ex- 
pected to facilitate  the exchange process of oxidized lipids 
between the cell membrane and LDL. 
A direct oxygenation of the LDL by the lipoxygenase re- 
quires a physical contact between the enzyme and the LDL 
particle.  It remains to be investigated how the intracellular 
enzyme comes in contact with the extracellular  LDL. Two 
possible pathways may be discussed. The first is internaliza- 
tion of the native LDL via the classical LDL receptor-mediated 
pathway and subsequent intracellular oxygenation as part of 
the metabolic breakdown of the particle. In this case, the ox- 
idative modification of LDL would depend on the expres- 
sion of the classical LDL receptor at the cell membrane. It 
has been shown before that arachidonic acid which is taken 
up by cells with the native LDL may be metabolized via 5-1i- 
poxygenase and  the  cyclooxygenase  pathway  after  being 
released from the LDL ester lipids in the lysosomes (38, 39). 
The second is extracelhlar localization of the 15-1ipoxygenase. 
In animal cells the 15-1ipoxygenase is synthesized as intracel- 
hlar protein. In rabbit reticulocytes,  there are no indications 
for an active transport of the enzyme across the cell mem- 
brane. However, we have immunohistochemical  evidence (im- 
munogold technique) of an extracelhlar localization of the 
15-1ipoxygenase  in human liver (Robenek, H., and H. Ktihn, 
unpublished data). Investigations of the subcelhlar localiza- 
tion of the 15-1ipoxygenase  in atherosclerotic lesions of humans 
and rabbit are currently being carried out in our laboratory. 
The oxygenation of free polyenoic fatty acids by lipoxy- 
genases leads to a highly specific product pattern. However, 
the in vitro oxygenation of complex substrates  such as bio- 
membranes and lipoproteins is characterized  by a share of 
stereorandom oxygenation products (19, 40) which some- 
times accounts for up to 40%  of the sum of oxygenation 
products.  With biomembranes this stereorandom share is 
strongly inhibited by radical scavengers such as BHT which 
is no inhibitor of the lipoxygenase reaction itself. These data 
suggested that free radicals may be involved in the formation 
of the unspecific products (40). Thus, the interaction of lipoxy- 
genase with complex substrates, particularly with LDL, may 
be regarded as source of lipid radicals. When formed in vivo, 
these radicals may induce damage to healthy tissue (41) and 
hence may contribute to the progression of atherosclerotic 
lesions. Radical scavengers which have been reported to slow 
down the progression of atherosclerosis (42, 43) may exhibit 
their beneficial effect by trapping these radicals. The lipoxy- 
genase or,  more precisely,  the hydroperoxy lipids formed 
during the lipoxygenase reaction are certainly not the only 
source for noxious radicals in atherosclerotic lesions.  Rad- 
icals may also be generated during cell death and necrosis 
which are characteristic  of advanced atherosclerotic plaques. 
The unspecific products of these reactions may swamp out 
the specific  products formed during the initial stages of plaque 
development. 
The physiological role of the 15-1ipoxygenase  in mammalian 
cells is still unclear.  Because of its capability  to oxygenate 
biomembranes the enzyme is implicated in membrane re- 
modeling and organel breakdown during the maturation of 
red blood cells (44, 45).  Similarly,  the enzyme may be in- 
volved in monocyte-macrophage  transition or in the matura- 
tion of tissue macrophages. Coming in contact with LDL 
outside the cell the 15-1ipoxygenase may catalyze the oxida- 
tive modification of LDL rendering these particles prone to 
macrophage uptake via scavenger receptor-mediated  pathways. 
On the other hand, the role of 15-1ipoxygenase in the patho- 
genesis of atherosderosis may not be limited to oxidative 
modification of LDL. Alternatively,  the enzyme may be ira- 
1909  K/ihn et al. portant for inflammatory reactions in the lesion. The specific 
induction of the 15-1ipoxygenase in human monocytes by the 
proinflammatory  IL-4 (36) supports this hypothesis.  Since 
inflammation may be regarded as a defense mechanism against 
endothelial injury in the early stages of plaque development, 
the action of the lipoxygenase might be involved in repair 
reactions. 
The degree of oxygenation of the tissue lipids of developing 
atherosclerotic lesions turned out to be an unsuitable mea- 
sure to characterize the stage of plaque development in early 
atherogenesis  for  two  reasons:  (a)  the  hydroxy  linoleic 
acid/linohic acid ratio ranging from 0.1 to 0.80 is usually 
very low in early atherosclerotic lesions and sometimes come 
dose to the detection limit of our HPLC diode array detector. 
(b) There are considerable interindividual differences that se- 
verely hamper statistical analysis with limited n-numbers. In 
later  stages of atherogenesis  and in particular  in advanced 
human atherosderotic lesions, the hydroxy iinoleic acid/linoleic 
acid ratio is much higher and may be used as reliable param- 
eter to quantify the degree of oxidative modification (23). 
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